Literature DB >> 15896973

Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.

Michel St-Hilaire1, Eric Landry, Daniel Lévesque, Claude Rouillard.   

Abstract

Motor complications induced through repeated L-DOPA treatment in patients with Parkinson's disease are thought to be the consequence of molecular adaptations that occur in response to repeated dopamine receptors stimulation. Here, we studied the molecular changes taking place in the denervated striatum of unilaterally 6-OHDA-lesioned rats repeatedly treated with L-DOPA alone or combined to the D1 receptor antagonist SCH23390. We looked at the territorial patterns of expression of neurotensin (NT), dynorphin (DYN), enkephalin (ENK) and Nur77 (also known as NGFI-B) mRNA expression in the striatum and contrasted these with markers of glutamatergic transport and dopaminergic receptor functions. The denervation process induced NT and Nur77 mRNA expression in ENK-positive cells. Subsequent repeated L-DOPA treatment led to a sensitization of L-DOPA-induced rotational response and produced a second surge of NT induction, this time limited to DYN-positive cells and preferentially restricted to the lateral striatum. In this specific territory, the number of Nur77-positive cells was decreased, in response to L-DOPA, when compared to the medial part of the lesioned striatum. L-DOPA treatment increased dopamine D3 receptor and glutamate transporter 1 (GLT1) mRNA expression in the lesioned striatum and that, specifically in an area overlapping one of Nur77 decrease and of NT/DYN induction. The concomitant administration of SCH23390 with repeated L-DOPA treatment blocked the development of behavioral sensitization and the appearance of all L-DOPA-induced molecular reorganizations reported above. Our results showed that repeated L-DOPA treatment produces, in a denervated striatum, a complex pattern of genes regulation in both the direct and the indirect striatal output pathways. This phenomenon is located preferentially in a striatal area receiving converging inputs from the thalamus and sensorimotor cortex and is dependent upon D1 receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896973     DOI: 10.1016/j.nbd.2005.04.001

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  19 in total

1.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

Review 2.  Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.

Authors:  Daniel Lévesque; Claude Rouillard
Journal:  Trends Neurosci       Date:  2006-11-28       Impact factor: 13.837

3.  Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.

Authors:  Souha Mahmoudi; Pershia Samadi; François Gilbert; Bazoumana Ouattara; Marc Morissette; Laurent Grégoire; Claude Rouillard; Thérèse Di Paolo; Daniel Lévesque
Journal:  Neurobiol Dis       Date:  2009-07-25       Impact factor: 5.996

4.  Repeated immobilization stress increases nur77 expression in the bed nucleus of the stria terminalis.

Authors:  Danae Campos-Melo; Gabriel Quiroz; Verónica Noches; Katia Gysling; María Inés Forray; María Estela Andrés
Journal:  Neurotox Res       Date:  2011-03-26       Impact factor: 3.911

5.  Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra.

Authors:  Jun Yang; Qingshan Teng; Mary E Garrity-Moses; Shearwood McClelland; Thais Federici; Erin Carlton; Jonathon Riley; Nicholas M Boulis
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

6.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

7.  Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

Authors:  Jenny E Westin; Linda Vercammen; Elissa M Strome; Christine Konradi; M Angela Cenci
Journal:  Biol Psychiatry       Date:  2007-07-26       Impact factor: 13.382

Review 8.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.

Authors:  Amanda L Sheldon; Michael B Robinson
Journal:  Neurochem Int       Date:  2007-04-19       Impact factor: 3.921

9.  Dopamine regulates the expression of the glutamate transporter GLT1 but not GLAST in developing striatal astrocytes.

Authors:  Veronica I Brito; Verena E Rozanski; Cordian Beyer; Eva Küppers
Journal:  J Mol Neurosci       Date:  2009-08-15       Impact factor: 3.444

10.  Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses.

Authors:  Yiyue Zhang; Gloria E Meredith; Nasya Mendoza-Elias; David J Rademacher; Kuei Y Tseng; Kathy Steece-Collier
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.